Development of a Scalable Process for the Synthesis of DNDI-VL-2098: A Potential Preclinical Drug Candidate for the Treatment of Visceral Leishmaniasis
A process suitable for kilogram-scale synthesis of (2R)-2-methyl-6-nitro-2-{[4-(trifluoromethoxy)phenoxy]methyl}-2,3-dihydroimidazo[2,1-b][1,3]oxazole (DNDI-VL-2098, 2), a preclinical drug candidate for the treatment of visceral leishmaniasis, is described. The four-step synthesis of the target...
Gespeichert in:
| Veröffentlicht in: | Organic process research & development 2017-01, Vol.21 (1), p.52-59 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 59 |
|---|---|
| container_issue | 1 |
| container_start_page | 52 |
| container_title | Organic process research & development |
| container_volume | 21 |
| creator | Satam, Vijay S Pedada, Srinivasa Rao Kamaraj, Pasumpon Antao, Nakita Singh, Apoorva Hindupur, Rama Mohan Pati, Hari N Thompson, Andrew M Launay, Delphine Martin, Denis |
| description | A process suitable for kilogram-scale synthesis of (2R)-2-methyl-6-nitro-2-{[4-(trifluoromethoxy)phenoxy]methyl}-2,3-dihydroimidazo[2,1-b][1,3]oxazole (DNDI-VL-2098, 2), a preclinical drug candidate for the treatment of visceral leishmaniasis, is described. The four-step synthesis of the target compound involves the Sharpless asymmetric epoxidation of 2-methyl-2-propen-1-ol, 8. Identification of a suitable synthetic route using retrosynthetic analysis and development of a scalable process to access several kilograms of 2 are illustrated. The process was simplified by employing in situ synthesis of some intermediates, reducing safety hazards, and eliminating the need for column chromatography. The improved reactions were carried out on the kilogram scale to produce 2 in good yield, high optical purity, and high quality. |
| doi_str_mv | 10.1021/acs.oprd.6b00331 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5437808</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1902479839</sourcerecordid><originalsourceid>FETCH-LOGICAL-a433t-3a30c146e1bc20bba58599266e0fbecdd4148a6b1c3ffb9a7d702bf9c52b4c3c3</originalsourceid><addsrcrecordid>eNp1UUtv1DAQthCIloU7J-QjB7L4kTgJB6Rql0elFVRqqbhZY2fSdZXEi51U6i_p362j3a7gwGks-XvNfIS85WzJmeAfwcal34VmqQxjUvJn5JQXgmVFpX4_T29WyUxxxU7IqxhvGWOF4uIlORFVIeuyyE_JwxrvsPO7HoeR-pYCvbTQgemQXgRvMUba-kDHLdLL-yGN6OKMW_9Yn2fXm0ywuvpEz-iFH5OCgy7R0HZucEmGrsN0Q1cwNK6BEY9KVwFhfHK8dtFiSOANurjtYXCQPF6TFy10Ed8c5oL8-vrlavU92_z8dr4622SQSzlmEiSzPFfIjRXMGCiqoq6FUshag7Zpcp5XoAy3sm1NDWVTMmHa2hbC5FZauSCf97q7yfTY2BQqZdG74HoI99qD0__-DG6rb_ydLnJZVum-C_L-IBD8nwnjqPt5oa6DAf0UNa-ZyMu6knWCsj3UBh9jwPZow5me-9SpTz33qQ99Jsq7v-MdCU8FJsCHPWCm3vopDOla_9d7BEuBrxc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1902479839</pqid></control><display><type>article</type><title>Development of a Scalable Process for the Synthesis of DNDI-VL-2098: A Potential Preclinical Drug Candidate for the Treatment of Visceral Leishmaniasis</title><source>American Chemical Society</source><creator>Satam, Vijay S ; Pedada, Srinivasa Rao ; Kamaraj, Pasumpon ; Antao, Nakita ; Singh, Apoorva ; Hindupur, Rama Mohan ; Pati, Hari N ; Thompson, Andrew M ; Launay, Delphine ; Martin, Denis</creator><creatorcontrib>Satam, Vijay S ; Pedada, Srinivasa Rao ; Kamaraj, Pasumpon ; Antao, Nakita ; Singh, Apoorva ; Hindupur, Rama Mohan ; Pati, Hari N ; Thompson, Andrew M ; Launay, Delphine ; Martin, Denis</creatorcontrib><description>A process suitable for kilogram-scale synthesis of (2R)-2-methyl-6-nitro-2-{[4-(trifluoromethoxy)phenoxy]methyl}-2,3-dihydroimidazo[2,1-b][1,3]oxazole (DNDI-VL-2098, 2), a preclinical drug candidate for the treatment of visceral leishmaniasis, is described. The four-step synthesis of the target compound involves the Sharpless asymmetric epoxidation of 2-methyl-2-propen-1-ol, 8. Identification of a suitable synthetic route using retrosynthetic analysis and development of a scalable process to access several kilograms of 2 are illustrated. The process was simplified by employing in situ synthesis of some intermediates, reducing safety hazards, and eliminating the need for column chromatography. The improved reactions were carried out on the kilogram scale to produce 2 in good yield, high optical purity, and high quality.</description><identifier>ISSN: 1083-6160</identifier><identifier>EISSN: 1520-586X</identifier><identifier>DOI: 10.1021/acs.oprd.6b00331</identifier><identifier>PMID: 28539754</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><ispartof>Organic process research & development, 2017-01, Vol.21 (1), p.52-59</ispartof><rights>Copyright © 2016 American Chemical Society</rights><rights>Copyright © 2016 American Chemical Society 2016 American Chemical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a433t-3a30c146e1bc20bba58599266e0fbecdd4148a6b1c3ffb9a7d702bf9c52b4c3c3</citedby><cites>FETCH-LOGICAL-a433t-3a30c146e1bc20bba58599266e0fbecdd4148a6b1c3ffb9a7d702bf9c52b4c3c3</cites><orcidid>0000-0001-6637-8004</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.oprd.6b00331$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.oprd.6b00331$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>230,314,780,784,885,2765,27076,27924,27925,56738,56788</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28539754$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Satam, Vijay S</creatorcontrib><creatorcontrib>Pedada, Srinivasa Rao</creatorcontrib><creatorcontrib>Kamaraj, Pasumpon</creatorcontrib><creatorcontrib>Antao, Nakita</creatorcontrib><creatorcontrib>Singh, Apoorva</creatorcontrib><creatorcontrib>Hindupur, Rama Mohan</creatorcontrib><creatorcontrib>Pati, Hari N</creatorcontrib><creatorcontrib>Thompson, Andrew M</creatorcontrib><creatorcontrib>Launay, Delphine</creatorcontrib><creatorcontrib>Martin, Denis</creatorcontrib><title>Development of a Scalable Process for the Synthesis of DNDI-VL-2098: A Potential Preclinical Drug Candidate for the Treatment of Visceral Leishmaniasis</title><title>Organic process research & development</title><addtitle>Org. Process Res. Dev</addtitle><description>A process suitable for kilogram-scale synthesis of (2R)-2-methyl-6-nitro-2-{[4-(trifluoromethoxy)phenoxy]methyl}-2,3-dihydroimidazo[2,1-b][1,3]oxazole (DNDI-VL-2098, 2), a preclinical drug candidate for the treatment of visceral leishmaniasis, is described. The four-step synthesis of the target compound involves the Sharpless asymmetric epoxidation of 2-methyl-2-propen-1-ol, 8. Identification of a suitable synthetic route using retrosynthetic analysis and development of a scalable process to access several kilograms of 2 are illustrated. The process was simplified by employing in situ synthesis of some intermediates, reducing safety hazards, and eliminating the need for column chromatography. The improved reactions were carried out on the kilogram scale to produce 2 in good yield, high optical purity, and high quality.</description><issn>1083-6160</issn><issn>1520-586X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp1UUtv1DAQthCIloU7J-QjB7L4kTgJB6Rql0elFVRqqbhZY2fSdZXEi51U6i_p362j3a7gwGks-XvNfIS85WzJmeAfwcal34VmqQxjUvJn5JQXgmVFpX4_T29WyUxxxU7IqxhvGWOF4uIlORFVIeuyyE_JwxrvsPO7HoeR-pYCvbTQgemQXgRvMUba-kDHLdLL-yGN6OKMW_9Yn2fXm0ywuvpEz-iFH5OCgy7R0HZucEmGrsN0Q1cwNK6BEY9KVwFhfHK8dtFiSOANurjtYXCQPF6TFy10Ed8c5oL8-vrlavU92_z8dr4622SQSzlmEiSzPFfIjRXMGCiqoq6FUshag7Zpcp5XoAy3sm1NDWVTMmHa2hbC5FZauSCf97q7yfTY2BQqZdG74HoI99qD0__-DG6rb_ydLnJZVum-C_L-IBD8nwnjqPt5oa6DAf0UNa-ZyMu6knWCsj3UBh9jwPZow5me-9SpTz33qQ99Jsq7v-MdCU8FJsCHPWCm3vopDOla_9d7BEuBrxc</recordid><startdate>20170120</startdate><enddate>20170120</enddate><creator>Satam, Vijay S</creator><creator>Pedada, Srinivasa Rao</creator><creator>Kamaraj, Pasumpon</creator><creator>Antao, Nakita</creator><creator>Singh, Apoorva</creator><creator>Hindupur, Rama Mohan</creator><creator>Pati, Hari N</creator><creator>Thompson, Andrew M</creator><creator>Launay, Delphine</creator><creator>Martin, Denis</creator><general>American Chemical Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6637-8004</orcidid></search><sort><creationdate>20170120</creationdate><title>Development of a Scalable Process for the Synthesis of DNDI-VL-2098: A Potential Preclinical Drug Candidate for the Treatment of Visceral Leishmaniasis</title><author>Satam, Vijay S ; Pedada, Srinivasa Rao ; Kamaraj, Pasumpon ; Antao, Nakita ; Singh, Apoorva ; Hindupur, Rama Mohan ; Pati, Hari N ; Thompson, Andrew M ; Launay, Delphine ; Martin, Denis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a433t-3a30c146e1bc20bba58599266e0fbecdd4148a6b1c3ffb9a7d702bf9c52b4c3c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Satam, Vijay S</creatorcontrib><creatorcontrib>Pedada, Srinivasa Rao</creatorcontrib><creatorcontrib>Kamaraj, Pasumpon</creatorcontrib><creatorcontrib>Antao, Nakita</creatorcontrib><creatorcontrib>Singh, Apoorva</creatorcontrib><creatorcontrib>Hindupur, Rama Mohan</creatorcontrib><creatorcontrib>Pati, Hari N</creatorcontrib><creatorcontrib>Thompson, Andrew M</creatorcontrib><creatorcontrib>Launay, Delphine</creatorcontrib><creatorcontrib>Martin, Denis</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Organic process research & development</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Satam, Vijay S</au><au>Pedada, Srinivasa Rao</au><au>Kamaraj, Pasumpon</au><au>Antao, Nakita</au><au>Singh, Apoorva</au><au>Hindupur, Rama Mohan</au><au>Pati, Hari N</au><au>Thompson, Andrew M</au><au>Launay, Delphine</au><au>Martin, Denis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of a Scalable Process for the Synthesis of DNDI-VL-2098: A Potential Preclinical Drug Candidate for the Treatment of Visceral Leishmaniasis</atitle><jtitle>Organic process research & development</jtitle><addtitle>Org. Process Res. Dev</addtitle><date>2017-01-20</date><risdate>2017</risdate><volume>21</volume><issue>1</issue><spage>52</spage><epage>59</epage><pages>52-59</pages><issn>1083-6160</issn><eissn>1520-586X</eissn><abstract>A process suitable for kilogram-scale synthesis of (2R)-2-methyl-6-nitro-2-{[4-(trifluoromethoxy)phenoxy]methyl}-2,3-dihydroimidazo[2,1-b][1,3]oxazole (DNDI-VL-2098, 2), a preclinical drug candidate for the treatment of visceral leishmaniasis, is described. The four-step synthesis of the target compound involves the Sharpless asymmetric epoxidation of 2-methyl-2-propen-1-ol, 8. Identification of a suitable synthetic route using retrosynthetic analysis and development of a scalable process to access several kilograms of 2 are illustrated. The process was simplified by employing in situ synthesis of some intermediates, reducing safety hazards, and eliminating the need for column chromatography. The improved reactions were carried out on the kilogram scale to produce 2 in good yield, high optical purity, and high quality.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>28539754</pmid><doi>10.1021/acs.oprd.6b00331</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-6637-8004</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-6160 |
| ispartof | Organic process research & development, 2017-01, Vol.21 (1), p.52-59 |
| issn | 1083-6160 1520-586X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5437808 |
| source | American Chemical Society |
| title | Development of a Scalable Process for the Synthesis of DNDI-VL-2098: A Potential Preclinical Drug Candidate for the Treatment of Visceral Leishmaniasis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A00%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20a%20Scalable%20Process%20for%20the%20Synthesis%20of%20DNDI-VL-2098:%20A%20Potential%20Preclinical%20Drug%20Candidate%20for%20the%20Treatment%20of%20Visceral%20Leishmaniasis&rft.jtitle=Organic%20process%20research%20&%20development&rft.au=Satam,%20Vijay%20S&rft.date=2017-01-20&rft.volume=21&rft.issue=1&rft.spage=52&rft.epage=59&rft.pages=52-59&rft.issn=1083-6160&rft.eissn=1520-586X&rft_id=info:doi/10.1021/acs.oprd.6b00331&rft_dat=%3Cproquest_pubme%3E1902479839%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1902479839&rft_id=info:pmid/28539754&rfr_iscdi=true |